Author

P. Masci

Observed names: P Masci, Paul A. Masci, Paul Masci

Institution: Cleveland Clinic

Observed institution: Cleveland Clinic

OpenAlex ID: A5046567271

A phase I clinical trial of a ribozyme-based angiogenesis inhibitor targeting vascular endothelial growth factor receptor-1 for patients with refractory solid tumors

2005 · David E. Weng, Paul A. Masci, et al. · Molecular Cancer Therapeutics · 75

Dendritic cells in autologous hematopoietic stem cell transplantation for diffuse large B-cell lymphoma: graft content and post transplant recovery predict survival

2005 · R Dean, P Masci, et al. · Bone Marrow Transplantation · 34

New and modified interferon alfas: Preclinical and clinical data

2003 · Paul Masci, Ronald M. Bukowski, et al. · Current Oncology Reports · 23

Gene Modulatory Effects, Pharmacokinetics, and Clinical Tolerance of Interferon-α1b: A Second Member of the Interferon-α Family

2007 · P Masci, T Olencki, et al. · Clinical Pharmacology & Therapeutics · 15

Malignant melanoma: treatments emerging, but early detection is still key.

2002 · P. Masci, E. C Borden · Cleveland Clinic Journal of Medicine · 9

Breast metastasis of ovarian cancer during cis-platinum therapy. A case report and review of the literature.

1985 · V Scotto, P Masci, et al. · PubMed · 4

A Phase II Trial of Doxil, Vincristine and Reduced Schedule Dexamethasone (DVd) for Patients with Relapsed or Refractory Multiple Myeloma.

2004 · Paul Masci, Mary A. Karam, et al. · Blood · 2

A Phase I evaluation of IFN α-1b in solid tumors, lymphoma or myeloma

2004 · P. Masci, L. Rybicki, et al. · Journal of Clinical Oncology

Works count: 8

Citation count: 162

H-index: 5

I10-index: 4